ストックスクリーナーアプリを入手
0.6604
5.66%
-0.0396
アフターアワーズ：
.65
-0.0104
-1.57%
Pds Biotechnology Corporation (PDSB) 最新ニュース
PDS Biotechnology (PDSB) CEO receives 548,782-share stock option award - Stock Titan
[Form 4] PDS Biotechnology Corp Insider Trading Activity - Stock Titan
PDS Biotechnology (PDSB) awards 150,000 stock options to Chief Scientific Officer - Stock Titan
PDS Biotechnology (PDSB) CMO receives grant of 300,000 stock options - Stock Titan
PDS Biotechnology (PDSB) director Ilian Iliev receives grant of 54,876 stock options - Stock Titan
Director option grant at PDS Biotechnology (PDSB) totals 54,876 options - Stock Titan
PDS Biotechnology (PDSB) director awarded 54,876 stock options in new grant - Stock Titan
PDS Biotechnology receives Nasdaq notice for minimum bid price deficiency - Investing.com
Nasdaq warns PDS Biotechnology (NASDAQ: PDSB) on $1.00 bid price rule - Stock Titan
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB) - The Wall Street Transcript
PDS Biotech Announces Amended Protocol for Phase 3 Trial - National Today
PDSB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
PDS Biotech (NASDAQ: PDSB) highlights HPV16 trial gains and pipeline - Stock Titan
Will PDS Biotechnology Corporation stock outperform Dow Jones indexMarket Movers & Consistent Profit Focused Trading Strategies - mfd.ru
PDS Biotechnology Amends Late-Stage Trial for PDS0101 to Support Accelerated Approval Pathway in HPV16-Positive Head and Neck Cancer - marketscreener.com
PDS Biotech amends Phase 3 trial to add accelerated approval path - Investing.com
LiveRamp Holdings, Inc. has announced a partnership with Scowtt - Bitget
Nucor has announced that Jack Sullivan has been promoted to Chief Financial Officer, Treasurer, and Executive Vice President of the company. - Bitget
PDS Biotechnology Corporation (PDS Biotech) recently announced that it has made significant amendments to the study protocol of its Phase III clinical trial, Versatile-003. - Bitget
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - The Manila Times
Cancer trial shift seeks faster PDS0101 bid for HPV16 head and neck patients - Stock Titan
Published on: 2026-02-19 10:39:09 - baoquankhu1.vn
PDS Biotechnology Approaches Critical Regulatory and Clinical Milestones - AD HOC NEWS
Is PDS Biotechnology Corporation likely to announce a buybackQuarterly Trade Review & AI Driven Price Predictions - mfd.ru
Can PDS Biotechnology Corporation stock outperform in a bear marketWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
PDS Biotech’s Big Bet Rides On Two Trial Readouts - Finimize
Growth Review: Can PDS Biotechnology Corporation stock outperform in a bear marketJuly 2025 Update & Weekly High Momentum Picks - baoquankhu1.vn
PDS Biotechnology: Regulatory Agreement Paves Way for Accelerated Cancer Therapy Review - AD HOC NEWS
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study By Investing.com - Investing.com South Africa
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study - Investing.com Nigeria
PDS Biotechnology Corporation Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - marketscreener.com
PDS Biotechnology Corporation Reports 9.6 Months Median Progression-Free Survival from NCI-Led Study of PDS01ADC in Advanced Prostate Cancer - Quiver Quantitative
PDS Biotech Announces Presentation of Preliminary Results - GlobeNewswire
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - The Manila Times
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com Nigeria
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
PDS Biotech secures patent for cancer immunotherapy PDS0101 - Investing.com
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - The Manila Times
Aug Macro: Can PDS Biotechnology Corporation stock outperform in a bear market2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Miss: Can STRW maintain sales growthMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Growth Value: Is PDS Biotechnology Corporation trading at a discount - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path By Investing.com - Investing.com South Africa
PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Nigeria
PDS Biotech Announces FDA Alignment on Use of Progression Free Survival as Primary Endpoint - marketscreener.com
PDS Biotech submits amended protocol for phase 3 cancer trial By Investing.com - Investing.com India
PDS Biotech Files Amended Protocol for Phase 3 VERSATILE-003 Trial to Seek Accelerated Approval of PDS0101 - Quiver Quantitative
Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan
How institutional buying supports PDS Biotechnology Corporation stockJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - Улправда
Is PDS Biotechnology Corporation stock resilient to inflation2025 Earnings Impact & AI Forecasted Entry/Exit Points - ulpravda.ru
Does PDS Biotechnology Corporation stock trade at a discount to peersM&A Rumor & Verified Short-Term Trading Plans - Улправда
PDS Biotechnology (NASDAQ:PDSB) Trading 5% Higher – Here’s Why - Defense World
Aug Sentiment: How PDS Biotechnology Corporation stock trades during market volatility2025 Pullback Review & Entry and Exit Point Strategies - Улправда
How interest rate cuts could boost PDS Biotechnology Corporation stockSell Signal & Reliable Entry Point Alerts - Улправда
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):